CoSyne Therapeutics Limited is a limited company established in 2021, operating from its headquarters at 2 Sheraton Street, London, W1F 8BH. The company’s primary focus is the development and application of advanced artificial intelligence (AI) technologies to accelerate drug discovery and personalize treatment for neurological diseases. CoSyne specializes in a vertically integrated approach, encompassing data acquisition, AI model development, clinical trial support, and regulatory pathway optimization. The company’s core service offering centers on utilizing sophisticated machine learning algorithms to analyze complex biological data – including genomic, proteomic, and imaging – identifying novel therapeutic targets and predicting drug efficacy with unprecedented speed. CoSyne’s expertise spans across multiple areas of neuroscience, including Alzheimer’s, Parkinson’s, and stroke research. CoSyne Therapeutics is currently active and seeks to expand its international presence through strategic partnerships and collaborations. The company is structured as a Ltd, with a workforce of approximately 50 skilled workers, representing a significant commitment to innovation and research. The company’s SIC codes include: - 72110: Research and experimental development on biotechnology, - 63111: Software and IT services.

CoSyne Therapeutics Limited is a limited company established in 2021, operating from its headquarters at 2 Sheraton Street, London, W1F 8BH. The company’s primary focus is the development and application of advanced artificial intelligence (AI) technologies to accelerate drug discovery and personalize treatment for neurological diseases. CoSyne specializes in a vertically integrated approach, encompassing data acquisition, AI model development, clinical trial support, and regulatory pathway optimization. The company’s core service offering centers on utilizing sophisticated machine learning algorithms to analyze complex biological data – including genomic, proteomic, and imaging – identifying novel therapeutic targets and predicting drug efficacy with unprecedented speed. CoSyne’s expertise spans across multiple areas of neuroscience, including Alzheimer’s, Parkinson’s, and stroke research. CoSyne Therapeutics is currently active and seeks to expand its international presence through strategic partnerships and collaborations. The company is structured as a Ltd, with a workforce of approximately 50 skilled workers, representing a significant commitment to innovation and research. The company’s SIC codes include: - 72110: Research and experimental development on biotechnology, - 63111: Software and IT services.